DNA

Helius (NASDAQ:HSDT), in Partnership with Pantera Capital and Summer Capital Announces Over $500 Million in Funding to Launch SOL Treasury Company

 Preeminent SOL-backed treasury vehicle - with potential to deliver over $1.25 billion - unlocks capital markets to accelerate Solana's growth...

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million...

Prenetics Announces Second Quarter 2025 Financial Results with IM8 on Track to Achieve $100M Annual Recurring Revenue by Year’s End

1st Half revenue grew 452.1% to $32.3 million YoY IM8 achieved $5.9 million revenue in August 2025, representing a CAGR1...

Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patientsConfirmed...

error: Content is protected !!